Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market

  • ID: 4071755
  • Report
  • Region: Global
  • 159 Pages
  • Ken Research Private Limited
1 of 5

FEATURED COMPANIES

  • Bayer AG
  • Boehringer Ingelheim
  • Janssen Pharmaceuticals
  • Pfizer Inc.
  • Sanofi
  • MORE

This publication on "Global Anticoagulants Market Outlook to 2020 - Demand for Patented NOACs with Prevalence of Cardiac Diseases to Drive Global Market" provides a comprehensive analysis of the anticoagulants market. The report includes the cumulative revenue generated by the market players from the sales of anticoagulants, including both generic and patented drugs at manufacturer's price and market share contributed by the sales of heparin, NOACs, Vitamin K Antagonists, and Injectable Direct Inhibitors in the total anticoagulants market. Further, the market in the study is differentiated on the basis of route of administration into oral and injectable. The market is also segmented by four geographical regions across the globe - North America, Europe, Asia Pacific, and Rest of the World. Detailed snapshot on key regions of the Market which includes North America, Europe, and Asia Pacific is included in the report to elucidate facts about the market in detail.

The study also highlights the detailed information about major drug manufacturers in the global anticoagulants market and their respective shares by revenue in 2015. Analysis on patented drugs available in the market, and their approval procedure, timeline, and expected expiries is provided in report to assist new entrants in understanding the market before investing in the market. Various marketing analysis factors such as trends and developments and Porter's five forces analysis are also added in the study for clear understanding about the factors responsible for present scenario of the market. The future analysis of overall global anticoagulants market has also been discussed along with recommendations from analyst view.

Key Topics Covered in the Report:

  • The market size of Global Anticoagulants Market
  • Market segmentation of Global Anticoagulants Market on the basis of Type, Route of Administration, and Geographical Analysis
  • Snapshot on North America Anticoagulants Market
  • Snapshot on Europe Anticoagulants Market
  • Snapshot on Asia Pacific Anticoagulants Market
  • Porter’s Five Forces Analysis for Global Anticoagulants Market
  • Trends and Developments in Global Anticoagulants Market
  • NOACs Drug Approval Timeline
  • NOACs Patent Expiries
  • Competitive Landscape and Detailed Company Profiles of the Major Market Players
  • Future Outlook and Projections of Global Anticoagulants Market
  • Analyst Recommendations
  • Macro-Economic Factors Impacting the Global Anticoagulants Market
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer AG
  • Boehringer Ingelheim
  • Janssen Pharmaceuticals
  • Pfizer Inc.
  • Sanofi
  • MORE

1. Executive Summary
Market Potential
Market Segmentation
Competitive Landscape
Future Outlook and Projections

2. Research Methodology
2.1. Market Definitions
2.2. Abbreviations
2.3. Market Size and Modeling
Approach - Market Sizing
Limitations

3. Introduction to Anticoagulants
Uses
Side Effects of Anticoagulants

4. Value Chain Analysis of Global Anticoagulants Market

5. Global Anticoagulants Market Size, 2013 - 2015

6. Global Anticoagulants Market Segmentation
6.1. By Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors), 2015
6.1.1. Heparin Market Segmentation by Type (Unfractionated and Low Molecular Weight Heparin)
6.1.2. NOACs Market Segmentation by Type (Rivaroxaban, Apixaban, Dabigatran Etexilate, and Edoxaban)
Drug Approval Timelines
Patent Expiries
6.2. By Route of Administration (Oral and Injectables)
6.3. By Geographical Regions (North America, Europe, Asia Pacific, and Rest of the World)

7. Snapshot on North America Anticoagulants Market
By Countries (US and Canada)
7.1. US Market Indicators
7.1.1. US Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
7.1.2. Key Anticoagulants in US
7.1.3. Regulatory Landscape
New Drug Approval Procedure
New Drug Timeline
Generic Drug Approval Procedure
Patents
Exclusivity
Anticoagulants Reimbursement Scenario in the US
7.2. Canada Market Indicators
7.2.1. Canada Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
7.2.2. Cost of Key Anticoagulants in Canada
7.2.1. Market Share of Major Players (Bayer Inc., Boehringer Ingelheim, and Bristol-Myers Squibb Canada Co) in Canada Anticoagulants Market, 2015
7.2.2. Regulatory Landscape
Generic Drug Approval Procedure
Patents and Exclusivity
Pharmaceutical Pricing and Reimbursement in Canada

8. Snapshot on Europe Anticoagulants Market
8.1. By Countries (Germany, France, Spain, Italy, UK, and Rest of the Europe)
8.2. Europe Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
8.2.1. Cost of Key Anticoagulants in Europe
8.3. Europe Anticoagulants Market by Companies (Bayer Inc., Boehringer Ingelheim, Pfizer, and Others)
8.4. Regulatory Landscape
8.4.1. New Drug Approval Procedure
8.4.2. Patents
8.4.3. Reimbursement Scenario in Europe

9. Snapshot on Asia Pacific Anticoagulants Market
By Countries (Japan, Australia, China, India, and Rest of the Asia Pacific)
9.1. Japan Market Indicators
9.1.1. Japan Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
9.1.2. Key Anticoagulants in Japan
9.1.3. Regulatory Landscape
New Drug Approval Procedure
Patents
9.2. Australia Market Indicators
9.2.1. Australia Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
9.2.2. Cost of Key Anticoagulants in Australia
9.2.3. Regulatory Landscape
New Drug Approval Procedure
Patents
Reimbursement Scenario in Australia
9.3. China Market Indicators
9.3.1. China Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
9.3.2. Cost of Key Anticoagulants in China
9.3.3. Market Share of Major Players (Bayer China, Boehringer Ingelheim, and Others) in China Anticoagulants Market, 2015
9.3.4. Regulatory Landscape
New Drug Approval Procedure
Patents
9.4. India Market Indicators
9.4.1. India Anticoagulants Market by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors)
9.4.1. Cost of Key Anticoagulants in India
9.4.2. Market Share of Major Players (Bayer India, Boehringer Ingelheim, Pfizer, GSK Pharmaceutical Ltd., Aventis Pharma and Others) in India Anticoagulants Market
9.4.3. Regulatory Landscape
New Drug Approval Procedure
Patents
Pricing and Reimbursement Scenario in India

10. Porter’s Five Forces Analysis for Global Anticoagulants Market

11. Trends and Developments in Global Anticoagulants Market
11.1. Expanding Therapeutic Indication
11.2. High incidence rate of DVT/PE
11.3. Disadvantages of Patented NOACs over Generic VKAs and Heparin Impacting Market Negatively

12. Global Anticoagulants Market Competitive Landscape
12.1. Market Share of Key Players in Global Anticoagulants Market, 2015
12.2. Company Profiles for Key Manufacturers in Anticoagulants Market
12.2.1. Sanofi
12.2.2. Pfizer Inc.
12.2.3. Boehringer Ingelheim
12.2.4. Bayer AG
12.2.5. Bristol-Myers Squibb Company
12.2.6. Daichi Sankyo company, Limited

13. Future of Global Anticoagulants Market
13.1. Future Outlook and Projections, 2016 - 2020

14. Analyst Recommendations

15. Macroeconomic Indicators
15.1. Aging Population
15.2. Deaths from Cardiovascular Diseases, 2010 - 2020
15.3. Healthcare Spending, 2010 - 2020

Disclaimer
Contact Us
 
List of Figures:
Figure 4-1: Value Chain Analysis of Global Anticoagulants Market
Figure 5-1: Global Anticoagulants Market on the basis of Revenue in USD Million, 2013 - 2015
Figure 6-1: Global Anticoagulants Market Segmentation by Type (Heparin, Novel Oral Anticoagulants, Vitamin K Antagonists, and Injectable Direct Inhibitors) on the basis of Revenue in Percentage, 2013 - 2015
Figure 6-2: Global Heparin Market Segmentation by Type (Unfractionated and Low Molecular Weight Heparin) on the basis of Revenue in Percentage, 2013 - 2015
Figure 6-3: Global NOACs Market Segmentation by Type (Rivaroxaban, Apixaban, Dabigatran Etexilate, and Edoxaban) on the basis of Revenue in Percentage, 2013 - 2015
Figure 6-4: Global Anticoagulants Market Segmentation by Route of Administration (Oral and Injectable) on the basis of Revenue in Percentage, 2013 - 2015
Figure 6-5: Global Anticoagulants Market Segmentation by Geographical Regions (North America, Europe, Asia Pacific and Rest of the World) on the basis of Revenue in Percentage, 2013 - 2015
Figure 7-1: North America Anticoagulants Market on the basis of Revenue in USD Million, 2013 - 2015
Figure 7-2: North America Anticoagulants Market Segmentation by Countries (US and Canada) on the basis of Revenue in terms of Percentage, 2013 - 2015
Figure 7-3: US Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of Percentage, 2013 - 2015
Figure 7-4: New Drug Approval Procedure in the US
Figure 7-5: New Drug Timeline in the US
Figure 7-6: ANDA Application Procedure for Generic Drug Approval in the US
Figure 7-7: Para IV Challenge against ANDA Paragraph IV Certification in the US
Figure 7-8: Patent Approval Procedure in the US
Figure 7-9: Canada Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of Percentage, 2013 - 2015
Figure 7-10: Drug Approval Procedure in Canada
Figure 8-1: Europe Anticoagulants Market on the basis of Revenue in USD Million, 2013 - 2015
Figure 8-2: Europe Anticoagulants Market Segmentation by Countries (Germany, France, Spain, Italy, UK, and Rest of the Europe) on the basis of Revenue in terms of Percentage, 2013 - 2015
Figure 8-3: Europe Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of Percentage, 2013 - 2015
Figure 8-4: Centralized Procedure for Drug Approval in Europe
Figure 8-5: Mutual Recognition Procedure for Drug Approval in Europe
Figure 8-6: Decentralized Procedure for Drug Approval in Europe
Figure 8-7: Patent Approval Procedure in Europe
Figure 9-1: Asia Pacific Anticoagulants Market on the basis of Revenue in USD Million, 2013 - 2015
Figure 9-2: Asia Pacific Anticoagulants Market Segmentation by Countries (Japan, Australia, China, India, and Rest of the Asia Pacific) on the basis of Revenue in terms of Percentage, 2013 - 2015
Figure 9-3: Japan Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of Percentage, 2013 - 2015
Figure 9-4: IND Approval Process in Japan
Figure 9-5: Drug Approval Process in Japan
Figure 9-6: Timeline for Approval of New Drug in Japan
Figure 9-7: Patent Approval Procedure in Japan
Figure 9-8: Australia Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of Percentage, 2013 - 2015
Figure 9-9: Drug Approval Procedure in Australia
Figure 9-10: Patent Approval Procedure in Australia
Figure 9-11: China Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of Percentage, 2013 - 2015
Figure 9-12: Application for Approval of Clinical Study in China
Figure 9-13: Clinical Studies Procedure in China
Figure 9-14: Final Approval Procedure for Drug Registration in China
Figure 9-15: Patent Approval Procedure in China
Figure 9-16: India Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of Percentage, 2013 - 2015
Figure 9-17: New Drug Approval Timeline in India
Figure 9-18: IND Application Procedure in India
Figure 9-19: NDA Approval Procedure in India
Figure 9-20: Patent Approval Procedure in India
Figure 10-1: Porters Five Forces Analysis for Global Anticoagulants Market
Figure 12-1: Financial Performance of Sanofi on the basis of Revenue Generated by Lovenox/Clexane in USD Million, 2013 - 2015
Figure 12-2: Financial Performance of Sanofi by Geographical Regions on the basis of Revenue Contribution by Lovenox/Clexane in terms of Percentages, 2015
Figure 12-3: Financial Performance of Pfizer on the basis of Revenue Generated by Fragmin in USD Million, 2013 - 2015
Figure 12-4: Financial Performance of Boehringer Ingelheim on the basis of Revenue Generated by Pradaxa in USD Million, 2013 - 2015
Figure 12-5: Financial Performance of Xarelto on the basis of Revenue in USD Million, 2013 - 2015
Figure 12-6: Financial Performance of Xarelto by Geographical Regions on the basis of Revenue in USD Million, 2013 - 2015
Figure 12-7: Financial Performance of Eliquis on the basis of Revenue in USD Million, 2013 - 2015
Figure 12-8: Financial Performance of Eliquis by Geographical Regions on the basis of Revenue in USD Million, 2013 - 2015
Figure 12-9: Financial Performance of Daichi Sankyo Company on the basis of Revenue Generated by Edoxaban in USD Million, 2013 - 2015
Figure 13-1: Global Anticoagulants Market Outlook and Future Projections on the basis of Revenue in USD Million, 2016 - 2020
Figure 13-2: Global Anticoagulants Market Segmentation Outlook and Future Projections by Type (Heparin, Novel Oral Anticoagulants, Vitamin K Antagonists, and Injectable Direct Inhibitors) on the basis of Revenue in Percentage, 2016 - 2020
Figure 13-3: Global Anticoagulants Market Segmentation Outlook and Future Projections by Geographical Regions (North America, Europe, Asia Pacific, and Rest of the World) on the basis of Revenue in Percentage, 2016 - 2020
Figure 15-1: Global Aging Population (People Above 65 years) in Millions, 2010 - 2020
Figure 15-2: Global Number of Deaths from Cardiovascular Diseases in Millions, 2010 - 2020
Figure 15-3: Global Healthcare Spending in USD Trillion, 2010 - 2020
Figure 15-4: Global Healthcare Spending by Public and Private Spending in Percentage, 2010 - 2020
 
List of Tables:
Table 4-1: Role of Various Stakeholders in the Value Chain of Global Anticoagulants Market
Table 5-1: Global Anticoagulants Market and Rationale for Revenue, 2013 - 2015
Table 6-1: Global Anticoagulants Market by Type (Heparin, Novel Oral Anticoagulants, Vitamin K Antagonists, and Injectable Direct Inhibitors) and Rationale for Revenue, 2015
Table 6-2: Comparison of Commonly Prescribed Anticoagulants on the basis of Indication, Dosing, Route of Administration, Dosage Modifications, and Cost of Treatment
Table 6-3: Global Anticoagulants Market Segmentation by Type (Heparin, Novel Oral Anticoagulants, Vitamin K Antagonists, and Injectable Direct Inhibitors) on the basis of Revenue in USD Million, 2013 - 2015
Table 6-4: Global Heparin Market by Type (Unfractionated and Low Molecular Weight Heparin) and Rationale for Revenue, 2015
Table 6-5: Key Heparin Drugs and their Generic Name, Route of Administration and Price
Table 6-6: Global Heparin Market Segmentation by Type (Unfractionated and Low Molecular Weight Heparin) on the basis of Revenue in USD Million, 2013 - 2015
Table 6-7: Global NOACs Market by Type (Rivaroxaban, Apixaban, Dabigatran Etexilate, and Edoxaban) and Rationale for Revenue, 2015
Table 6-8: Comparative Analysis of NOACs on the basis of Bioavailability, Time to Cmax, Half Life, Drug Interaction Concerns, Adjustment for Renal Function, Other Adjustments, Bleed Rates, Major or Common Side Effects, Effects on Common Coagulation Labs, Dosing Frequency and Unique Point
Table 6-9: Rivaroxaban Approval Timeline
Table 6-10: Apixaban Approval Timeline
Table 6-11: Edoxaban Approval Timeline
Table 6-12: Dabigatran Etexilate Approval Timeline
Table 6-13: Patent Expiries of NOACs by Countries
Table 6-14: Global NOACs Market Segmentation by Type (Rivaroxaban, Apixaban, Dabigatran Etexilate, and Edoxaban) on the basis of Revenue in USD Million, 2013 - 2015
Table 6-15: Global Anticoagulants Market by Route of Administration (Oral and Injectables) and Rationale for Revenue, 2015
Table 6-16: Global Anticoagulants Market Segmentation by Route of Administration (Oral and Injectable) on the basis of Revenue in USD Million, 2013 - 2015
Table 6-17: Global Anticoagulants Market by Geographical Regions (North America, Europe, Asia Pacific and Rest of the World) and Rationale for Revenue, 2013 - 2015
Table 6-18: Global Anticoagulants Market Segmentation by Geographical Regions (North America, Europe, Asia Pacific and Rest of the World) on the basis of Revenue in USD Million, 2013 - 2015
Table 7-1: Snapshot on North America Anticoagulants Market
Table 7-2: North America Anticoagulants Market Segmentation by Countries (US and Canada) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 7-3: Prevalence of Major Disease Indications for which Anticoagulants are used in the US
Table 7-4: US Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 7-5: Key Branded Drugs in the US, Company and their Sales in terms of USD Million, 2013 - 2015
Table 7-6: US Anticoagulants Market Segmentation by Companies (Janssen Pharmaceuticals, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, and Others) on the basis of Revenue, 2015
Table 7-7: Drug Approval Applications, Rationale, and Fees in the US, 2016
Table 7-8: Types of Drug Exclusivity, Rationale, and Time Period of Exclusivity
Table 7-9: Prevalence of Major Disease Indications for which Anticoagulants are used in Canada
Table 7-10: Canada Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 7-11: Key Branded Anticoagulants in Canada, Company and its Average Price
Table 7-12: Market Share of Major Players (Bayer Inc., Boehringer Ingelheim, Bristol Myers Squibb Canada Co, and Others) in Canada Anticoagulants Market on the basis of Revenue, 2015
Table 7-13: Patent and Exclusivity Procedure in Canada and Rationale
Table 8-1: Prevalence of Major Disease Indications for which Anticoagulants are used in Europe
Table 8-2: Snapshot on Europe Anticoagulants Market
Table 8-3: Europe Anticoagulants Market Segmentation by Countries (Germany, Spain, Italy, France, UK, and Rest of the Europe) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 8-4: Europe Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 8-5: Key Branded Anticoagulants in Europe, Company and its Average Price
Table 8-6: Europe Anticoagulants Market Segmentation by Companies (Bayer Inc., Boehringer Ingelheim, Bristol Myers Squibb, and Others) on the basis of Revenue, 2015
Table 8-7: Product Price Regulation in Europe by Countries, 2016
Table 8-8: Control of Expenditure in Europe by Countries, 2016
Table 8-9: Industry Regulations in Europe by Countries, 2016
Table 8-10: Product Reimbursement  in Europe by Countries, 2016
Table 9-1: Snapshot on Asia Pacific Anticoagulants Market
Table 9-2: Asia Pacific Anticoagulants Market Segmentation by Countries (Japan, Australia, China, India, and Rest of the Asia Pacific) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-3: Prevalence of Major Disease Indications for which Anticoagulants are used in Japan
Table 9-4: Japan Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-5: Key Branded Anticoagulants in Japan, and Company
Table 9-6: Prevalence of Major Disease Indications for which Anticoagulants are used in Australia
Table 9-7: Australia Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-8: Key Branded Anticoagulants in Australia, Company and Average Price in USD
Table 9-9: Prevalence of Major Disease Indications for which Anticoagulants are used in China
Table 9-10: China Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-11: Key Branded Drugs in the China, Company. Price and their Estimated Sales in terms of USD Million, 2013 - 2015
Table 9-12: Market Share of Major Players (Bayer Inc., Boehringer Ingelheim, Bristol Myers Squibb, and Others) in China Anticoagulants Market on the basis of Revenue, 2015
Table 9-13: Prevalence of Major Disease Indications for which Anticoagulants are used in India
Table 9-14: India Anticoagulants Market Segmentation by Type (Heparin, NOACs, VKAs, and Injectable Direct Inhibitors) on the basis of Revenue in terms of USD Million, 2013 - 2015
Table 9-15: Key Branded Drugs in the India, Company. Price and their Estimated Sales in terms of USD Million, 2013 - 2015
Table 9-16: Market Share of Major Players (Bayer India, Boehringer Ingelheim, Pfizer, GSK Pharmaceutical Ltd., Aventis Pharma and Others) in India Anticoagulants Market on the basis of Revenue, 2015
Table 10-1: Porter’s Five Forces Analysis for Global Anticoagulants Market
Table 12-1: Global Anticoagulants Market by Manufacturers and Rationale for Revenue, 2015
Table 12-2: Market Share of Major Players (Bayer AG, Boehringer Ingelheim, Bristol-Myers Squibb Company, Sanofi, Pfizer Inc., Janssen Pharmaceuticals and Others) in Global Anticoagulants Market on the Basis of Revenue, 2015
Table 12-3: Competitive Landscape of Sanofi including Company Overview, Global Footprints, Product Portfolio, Business Strategies, Number of Employees, and Key Personnel
Table 12-4: Competitive Landscape of Pfizer Inc. including Company Overview, Global Footprints, Product Portfolio, Business Strategies, Research and Development, Number of Employees, and Key Personnel
Table 12-5: Company Profile of Boehringer Ingelheim including Company Overview, Global Footprints, Business Strategies, and Number of Employees
Table 12-6: Company Profile of Bayer AG including Company Overview, Global Footprints, Business Strategies, and Number of Employees
Table 12-7: Company Profile of Bristol-Myers Squibb Company including Company Overview, Global Footprints, Business Strategies, and Number of Employees
Table 12-8: Company Profile of Daichi Sankyo Company, Limited including Company Overview, Global Footprints, Business Strategies, and Number of Employees
Table 13-1: Future Drivers for Global Anticoagulants Market
Table 13-2: Global Anticoagulants Market Segmentation Outlook and Future Projections by Type (Heparin, Novel Oral Anticoagulants, Vitamin K Antagonists, and Injectable Direct Inhibitors) on the basis of Revenue in USD Million, 2016 - 2020
Table 13-3: Global Anticoagulants Market Segmentation Outlook and Future Projections by Geographical Regions (North America, Europe, Asia Pacific, and Rest of the World) on the basis of Revenue in USD Million, 2016 - 2020
Table 14-1: Recommendations for Global Anticoagulants Market
Table 15-1: Rationale for Global Aging Population, 2010 - 2020
Table 15-2: Rationale for Global Deaths from Cardiovascular Diseases, 2010 - 2020
Table 15-3: Rationale for Global Healthcare Spending, 2010 - 2020

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bayer AG
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Daichi Sankyo Company Limited
  • Janssen Pharmaceuticals
  • Pfizer Inc.
  • Sanofi
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll